{"preliminary_commentary":{"by_channel":{"podcast":14,"youtube":10,"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05512364\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TREAT ctDNA","nct_id":"NCT05512364","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=treat-ctdna-nct05512364. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TREAT ctDNA","arms":[{"description":"elacestrant 400 mg/day orally once daily on a continuous dosing schedule","label":"Experimental arm","type":"EXPERIMENTAL"},{"description":"standard endocrine treatment - the same they were receiving at the time of ctDNA detection","label":"Control arm","type":"ACTIVE_COMPARATOR"}],"collaborators":["Menarini Group","Natera, Inc.","Borstkanker Onderzoek Groep","Cancer Trials Ireland","SOLTI Breast Cancer Research Group","ETOP IBCSG Partners Foundation","SUCCESS","Hellenic Cooperative Oncology Group","Hellenic Oncology Research Group","Swedish Breast Cancer Group"],"completion_date":{"date":"2035-11-01","type":"ESTIMATED"},"conditions":["ER-positive Breast Cancer","HER2-negative Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer"],"enrollment":{"count":220,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elacestrant","otherNames":[],"type":"DRUG"},{"name":"Tamoxifen","otherNames":[],"type":"DRUG"},{"name":"Letrozole 2.5mg","otherNames":[],"type":"DRUG"},{"name":"Anastrozole 1mg","otherNames":[],"type":"DRUG"},{"name":"Exemestane 25 MG","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Distant metastasis free survival (DMFS)","timeFrame":"Final DFMS will be 6.25 years after the first patient randomised."}],"references":[],"start_date":{"date":"2023-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","url":"https://clinicaltrials.gov/study/NCT05512364"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/treat-ctdna-nct05512364"}